Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Clinical trial NCT04655976 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04655976
Sponsor: GlaxoSmithKline
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Lung Cancer, Non-Small Cell

Start date: 2020-12-08
Primary completion: 2025-06-05
Enrollment: 758

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.